Correction: The Role of Interleukin−6 in Prematurity Complications: Transitioning from Biomarker to Therapeutic Target
-
By
-
Shuzhe Xiao
-
Qi Zheng
-
Lingling Wang
-
Zhiqiu Wang
-
Guangliang Bi
-
Jie Yang
-
September 10, 2026
Clinical Scorecard: Correction: The Role of Interleukin−6 in Prematurity Complications: Transitioning from Biomarker to Therapeutic Target
At a Glance
| Category | Detail |
|---|
| Condition | Complications of Prematurity |
| Key Mechanisms | IL-6 signaling through the JAK/STAT pathway mediates pro-inflammatory and pro-fibrotic effects. |
| Target Population | Preterm infants |
| Care Setting | Neonatal Intensive Care Unit (NICU) |
Key Highlights
- IL-6 is associated with complications such as BPD, NES, ROP, AKI, NEC, and HIE.
- Elevated IL-6 levels can predict complications in preterm infants.
- IL-6 peaks six hours after inflammation begins, declining over the next 48 hours.
Guideline-Based Recommendations
Diagnosis
- IL-6 is a significant biomarker for early-onset neonatal sepsis (NES).
Management
- Research is ongoing to establish IL-6 thresholds for sepsis diagnosis in preterm infants.
Monitoring & Follow-up
- Monitor IL-6 levels for predicting complications in preterm infants.
Risks
- Complications from prematurity can lead to significant health issues and mortality.
Patient & Prescribing Data
Preterm infants at risk for complications.
IL-6 may serve as a therapeutic target in managing complications associated with prematurity.
Clinical Best Practices
- Utilize IL-6 levels in conjunction with other biomarkers for diagnosing NES.
- Consider IL-6 thresholds in clinical decision-making for preterm infants.
Related Resources & Content
